PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Seaport Therapeutics reported positive Phase 1 multiple-ascending dose (MAD) data for GlyphAgo, its novel oral prodrug of agomelatine. The trial involved 174 healthy volunteers and showed that seven-day dosing achieved therapeutic exposures with no liver-related adverse events, addressing a key limitation of unmodified agomelatine.
Key figures
- Drug Name
- GlyphAgo (SPT-320)
- Phase Of Trial
- Phase 1
- Participants
- 174
- Bioavailability increase
- 6.8-fold
- Pk variability reduction
- 10-fold
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.